JP2023519100A - 抗acvr1抗体およびその使用 - Google Patents

抗acvr1抗体およびその使用 Download PDF

Info

Publication number
JP2023519100A
JP2023519100A JP2022548596A JP2022548596A JP2023519100A JP 2023519100 A JP2023519100 A JP 2023519100A JP 2022548596 A JP2022548596 A JP 2022548596A JP 2022548596 A JP2022548596 A JP 2022548596A JP 2023519100 A JP2023519100 A JP 2023519100A
Authority
JP
Japan
Prior art keywords
antibody
acvr1
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519100A5 (cg-RX-API-DMAC7.html
Inventor
ヴィンセント・ジェイ・イドン
サラ・ジェイ・ハットセル
アリス・エヌ・エコノマイズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023519100A publication Critical patent/JP2023519100A/ja
Publication of JP2023519100A5 publication Critical patent/JP2023519100A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022548596A 2020-02-11 2021-02-10 抗acvr1抗体およびその使用 Pending JP2023519100A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062975047P 2020-02-11 2020-02-11
US62/975,047 2020-02-11
US202063030131P 2020-05-26 2020-05-26
US63/030,131 2020-05-26
PCT/US2021/017427 WO2021163170A1 (en) 2020-02-11 2021-02-10 Anti-acvr1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023519100A true JP2023519100A (ja) 2023-05-10
JP2023519100A5 JP2023519100A5 (cg-RX-API-DMAC7.html) 2024-02-22

Family

ID=74860418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548596A Pending JP2023519100A (ja) 2020-02-11 2021-02-10 抗acvr1抗体およびその使用

Country Status (11)

Country Link
US (2) US11945872B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103617A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023519100A (cg-RX-API-DMAC7.html)
KR (1) KR20220140802A (cg-RX-API-DMAC7.html)
CN (1) CN115362175A (cg-RX-API-DMAC7.html)
AU (1) AU2021218675A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167441A1 (cg-RX-API-DMAC7.html)
IL (1) IL295419A (cg-RX-API-DMAC7.html)
MX (1) MX2022009769A (cg-RX-API-DMAC7.html)
WO (1) WO2021163170A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208222B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN119529092A (zh) * 2021-09-03 2025-02-28 来凯医药科技(上海)有限公司 抗acvr2a抗体及其用途
WO2024092133A1 (en) 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗alk2抗体
WO2019172165A1 (ja) * 2018-03-05 2019-09-12 学校法人埼玉医科大学 異所性骨化の治療又は予防のための医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8859752B2 (en) 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
US8895711B2 (en) * 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RS53258B (sr) 2007-02-21 2014-08-29 University Of Massachusetts Humana antitela protiv virusa hepatitisa c (hcv) i njihove upotrebe
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US9840557B2 (en) * 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
KR20210038906A (ko) * 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
EP4008350A4 (en) 2019-07-26 2023-06-14 Saitama Medical University ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗alk2抗体
WO2019172165A1 (ja) * 2018-03-05 2019-09-12 学校法人埼玉医科大学 異所性骨化の治療又は予防のための医薬組成物

Also Published As

Publication number Publication date
WO2021163170A1 (en) 2021-08-19
CA3167441A1 (en) 2021-08-19
ZA202208222B (en) 2023-10-25
IL295419A (en) 2022-10-01
EP4103617A1 (en) 2022-12-21
US11945872B2 (en) 2024-04-02
AU2021218675A1 (en) 2022-08-18
KR20220140802A (ko) 2022-10-18
US20210253716A1 (en) 2021-08-19
US20240190974A1 (en) 2024-06-13
MX2022009769A (es) 2022-11-09
CN115362175A (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
JP7271637B2 (ja) 抗psma抗体、psma及びcd3と結合する二重特異性抗原結合分子、ならびにその使用
JP6865324B2 (ja) 抗cd3抗体、cd3及びcd20に結合する二重特異性抗原結合分子、並びにそれらの使用
JP7165225B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
TWI838389B (zh) 雙特異性抗-BCMAx抗-CD3抗體及其用途
JP7023231B2 (ja) 最適化抗cd3二重特異性抗体及びその使用
US9890212B2 (en) Antibodies to human GDF8
JP6581075B2 (ja) ヒト抗grem1抗体
JP6367233B2 (ja) 抗pdgfr−ベータ抗体及びそれらの使用
US11945872B2 (en) Anti-ACVR1 antibodies and uses thereof
CN113661177A (zh) EGFR x CD28多特异性抗体
MX2014011898A (es) Anticuerpos anti-hla-b*27 y usos de estos.
CA2902572A1 (en) Human antibodies to nav1.7
CA3019740A1 (en) Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
JP2025138816A (ja) 骨形成タンパク質6に対するヒト抗体
US20180208656A1 (en) Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof
EA049583B1 (ru) Анти-acvr1 антитела и их применение
US20260000758A1 (en) Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
US20240150474A1 (en) Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification
TW202519547A (zh) 雙特異性PD-L1x4-1BB抗體及其使用方法
EA046104B1 (ru) Анти-npr1 антитела и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260326

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260803